ACADIA Pharmaceuticals Inc. (ACAD)
ACAD Stock Price Chart
Explore ACADIA Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze ACAD price movements and trends.
ACAD Company Profile
Discover essential business fundamentals and corporate details for ACADIA Pharmaceuticals Inc. (ACAD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 May 2004
Employees
653.00
Website
https://www.acadia-pharm.comCEO
Catherine E. Owen Adams
Description
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
ACAD Financial Timeline
Browse a chronological timeline of ACADIA Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is $0.05, while revenue estimate is $295.83m.
Earnings released on 6 May 2026
EPS came in at $0.02 falling short of the estimated $0.04 by -50.00%, while revenue for the quarter reached $268.10m , missing expectations by -4.34%.
Earnings released on 25 Feb 2026
EPS came in at $1.60 surpassing the estimated $0.14 by +1.07k%, while revenue for the quarter reached $283.99m , missing expectations by -3.00%.
Earnings released on 5 Nov 2025
EPS came in at $0.26 surpassing the estimated $0.14 by +85.71%, while revenue for the quarter reached $278.63m , missing expectations by -4.77%.
Earnings released on 6 Aug 2025
EPS came in at $0.16 surpassing the estimated $0.14 by +14.29%, while revenue for the quarter reached $264.57m , beating expectations by +0.98%.
Earnings released on 7 May 2025
EPS came in at $0.11 surpassing the estimated $0.10 by +10.00%, while revenue for the quarter reached $244.32m , beating expectations by +2.24%.
Earnings released on 26 Feb 2025
EPS came in at $0.17 surpassing the estimated $0.13 by +30.77%, while revenue for the quarter reached $259.60m , missing expectations by -4.92%.
Earnings released on 6 Nov 2024
EPS came in at $0.20 surpassing the estimated $0.14 by +42.86%, while revenue for the quarter reached $250.40m , missing expectations by -11.49%.
Earnings released on 6 Aug 2024
EPS came in at $0.20 surpassing the estimated $0.18 by +11.11%, while revenue for the quarter reached $241.96m , beating expectations by +2.78%.
Earnings released on 8 May 2024
EPS came in at $0.10 surpassing the estimated $0.05 by +100.00%, while revenue for the quarter reached $205.83m , missing expectations by -1.18%.
Earnings released on 27 Feb 2024
EPS came in at $0.28 falling short of the estimated $0.30 by -6.67%, while revenue for the quarter reached $231.04m , beating expectations by +3.24%.
Earnings released on 2 Nov 2023
EPS came in at -$0.40 surpassing the estimated -$0.43 by +6.98%, while revenue for the quarter reached $211.70m , missing expectations by -5.65%.
Earnings released on 2 Aug 2023
EPS came in at $0.01 surpassing the estimated -$0.12 by +108.33%, while revenue for the quarter reached $165.24m , beating expectations by +4.68%.
Earnings released on 8 May 2023
EPS came in at -$0.27 falling short of the estimated -$0.21 by -28.57%, while revenue for the quarter reached $118.46m , missing expectations by -1.35%.
Earnings released on 27 Feb 2023
EPS came in at -$0.26 falling short of the estimated -$0.25 by -4.00%, while revenue for the quarter reached $136.49m , beating expectations by +1.68%.
Earnings released on 2 Nov 2022
EPS came in at -$0.17 surpassing the estimated -$0.18 by +5.56%, while revenue for the quarter reached $130.71m , missing expectations by -5.80%.
Earnings released on 8 Aug 2022
EPS came in at -$0.21 surpassing the estimated -$0.25 by +16.00%, while revenue for the quarter reached $134.56m , beating expectations by +3.19%.
Earnings released on 4 May 2022
EPS came in at -$0.70 falling short of the estimated -$0.49 by -42.86%, while revenue for the quarter reached $115.47m , missing expectations by -5.29%.
Earnings released on 28 Feb 2022
EPS came in at -$0.27 falling short of the estimated -$0.24 by -12.50%, while revenue for the quarter reached $130.76m , missing expectations by -3.42%.
Earnings released on 8 Nov 2021
EPS came in at -$0.09 surpassing the estimated -$0.27 by +66.67%, while revenue for the quarter reached $131.61m , missing expectations by -2.78%.
Earnings released on 4 Aug 2021
EPS came in at -$0.27 surpassing the estimated -$0.30 by +10.00%, while revenue for the quarter reached $115.22m , meeting expectations.
ACAD Stock Performance
Access detailed ACAD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
